Cadrenal Therape Stock Price, News & Analysis

Cadrenal Therapeutics (Nasdaq: CVKD) has announced plans to initiate clinical trials for tecarfarin, its lead late-stage drug candidate, targeting patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis. The trials, set to begin in late 2025, will include patients both with and without atrial fibrillation (AFib).

Tecarfarin, which has received orphan drug and fast-track designations for ESKD patients with AFib, represents a potential breakthrough as a next-generation Vitamin K antagonist. The drug's unique metabolism pathway is not significantly affected by kidney impairment, addressing a critical treatment gap for dialysis patients who are typically excluded from clinical trials due to high risk profiles.

Cadrenal Therapeutics (NASDAQ: CVKD) has revealed new third-party research highlighting the significant medical and economic challenges faced by LVAD patients requiring chronic anticoagulation. The research, conducted by Guidehouse, shows substantial hospitalization costs for major bleeding events: $54,100 for intracranial hemorrhage, $26,900 for gastrointestinal bleeds, and $36,600 for other major bleeds. The company's Phase 3-ready drug tecarfarin is positioned as a potential alternative to warfarin for LVAD patients. Tecarfarin's key advantage lies in its novel metabolic pathway through a single enzyme (CES2), which may reduce drug interactions, dietary complications, and adverse bleeding or thrombotic events compared to warfarin's multiple metabolic pathways.

Cadrenal Therapeutics (NASDAQ: CVKD), a biopharmaceutical company focused on cardiovascular disease treatments, announced its participation in the BIO International Convention 2025, scheduled for June 16-19 in Boston. The company's executive team will engage in one-on-one meetings with investors and potential partners to discuss their strategic direction and provide updates on tecarfarin, their lead drug candidate. The BIO International Convention is recognized as the largest biotechnology event globally, attracting over 20,000 industry leaders from the life sciences sector. Interested parties can schedule meetings through the Conference portal or by contacting the company's Investor Relations.

Cadrenal Therapeutics (NASDAQ: CVKD) has achieved key manufacturing milestones for tecarfarin, its lead drug candidate. The company successfully completed the technical transfer and manufacturing of tecarfarin drug substance under cGMP standards at a U.S.-based CDMO facility earlier this year. The manufacturing of the drug product candidate is currently in progress.

Tecarfarin is a novel oral vitamin K antagonist (VKA) anticoagulant designed to address unmet needs in anticoagulation therapy for patients with cardiovascular disease. The manufacturing progress represents a significant step in supporting the company's clinical development strategy.

Cadrenal Therapeutics (NASDAQ: CVKD) reported its Q1 2025 financial results and corporate updates. Key highlights include: appointment of Dr. James Ferguson as Chief Medical Officer, a successful FDA Type D Meeting providing guidance for tecarfarin's Phase 3 trial, and a Collaboration Agreement with Abbott for the TECH-LVAD trial. The company completed technical transfer of tecarfarin manufacturing to a U.S. CDMO and conducted market research showing growth potential in the LVAD market. Financial results show R&D expenses of $1.7M (up from $0.6M in Q1 2024), G&A expenses of $2.3M (up from $1.1M), and a net loss of $3.8M. Cash position stands at $7.3M as of March 31, 2025, down from $10.0M at year-end 2024.

Cadrenal Therapeutics (CVKD) has announced its participation in the inaugural Centri Capital Conference, scheduled to take place at Nasdaq in New York City on April 22, 2025. Chairman and CEO Quang X. Pham will deliver a company presentation and provide updates on tecarfarin, the company's lead asset.

Tecarfarin, a Phase 3-ready oral vitamin K antagonist anticoagulant, is being developed to address unmet needs in anticoagulation therapy. The conference will bring together capital markets representatives and investment community members, focusing on companies innovating in healthcare and life sciences sectors.

Cadrenal Therapeutics (NASDAQ: CVKD) has announced its participation in several key medical and business development conferences during Q2 2025. The company, which is developing tecarfarin, a Phase 3-ready oral vitamin K antagonist anticoagulant, will be represented at:

• 18th National Conference on Anticoagulation Therapy in Washington, D.C. (April 3-5)
• 13th annual CMO Summit 360° ® (April 7-8)
• BIO International Convention in Boston, MA (June 16-19)

Chief Operating Officer Jeff Cole and Chief Medical Officer Dr. James Ferguson will attend these events to engage with industry experts, key opinion leaders, and potential partners to advance tecarfarin development and build their specialized cardiovascular therapeutics pipeline.

Cadrenal Therapeutics (NASDAQ: CVKD) reported its full year 2024 results and updates on tecarfarin development. The company secured a collaboration with Abbott for the TECH-LVAD Phase 3 trial and received additional FDA guidance through a Type D meeting.

Key financial highlights include:

• Net loss of $10.7M in 2024 vs $8.4M in 2023
• R&D expenses of $4.2M vs $4.1M in 2023
• G&A expenses increased to $6.8M from $3.5M
• Cash position of $10.0M as of December 31, 2024
• Raised $9.8M through ATM facility ($5.1M) and warrant exercises ($4.7M)

Notable achievements include FDA Orphan Drug Designation for tecarfarin in mechanical circulatory support devices, appointment of new executive leadership, and completion of manufacturing readiness for Phase 3 trial materials.

Cadrenal Therapeutics (CVKD) has announced a significant collaboration agreement with Abbott (ABT) to support their pivotal TECH-LVAD trial, evaluating tecarfarin in patients with Left Ventricular Assist Devices (LVADs).

The collaboration focuses on testing tecarfarin, a new oral Vitamin K antagonist (VKA), with Abbott's HeartMate 3™ LVAD, which is currently the only advanced mechanical circulatory support device available in the United States for patients with advanced heart failure.

Under the agreement, Abbott will provide support in:

• Trial design
• Site identification
• Trial awareness
• HeartMate 3™ expertise

The LVAD market, valued at $1.1 billion in 2023, is projected to reach $2.4 billion by 2032, according to Business Research Insights.